Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice

JG Gribben, F Bosch, F Cymbalista, CH Geisler, P Ghia, P Hillmen, C Moreno, S Stilgenbauer

Research output: Contribution to journalArticle

Abstract

© 2018 John Wiley & Sons Ltd Ibrutinib is indicated in Europe for the treatment of several B-cell malignancies, including chronic lymphocytic leukaemia (CLL). However, despite the high efficacy and favourable toxicity profile of ibrutinib, recent data suggest that it is not always administered optimally in clinical practice, with an increased tendency for dose reduction and a higher frequency of discontinuation. An expert panel of European haematologists was convened to identify practical issues pertinent to physicians involved in the therapeutic management of ibrutinib-treated CLL patients and here we outline the findings. Practical management recommendations are given for treating patients with ibrutinib and clinical considerations for the management of adverse events (AEs) that can be associated with ibrutinib treatment are addressed. This article highlights that patients should be monitored for treatment emergent adverse events, most of which are mild, transient and generally occur early in therapy and that, even with more challenging AEs, patients can often be maintained on therapy with minimal disruption through careful management. The necessity to use the correct ibrutinib dose, along with increased awareness, vigilance, mitigation and management of AEs, are all recommended to maximise outcomes for CLL patients treated with ibrutinib. © 2018 John Wiley & Sons Ltd
Original languageEnglish
Pages (from-to)666-679
Number of pages14
JournalBritish Journal of Haematology
Volume180
Issue number5
DOIs
Publication statusPublished - 2018

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Nuclear Family
Therapeutics
Secondary Prevention
PCI 32765
B-Lymphocytes
Physicians
Neoplasms

Cite this

Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. / Gribben, JG; Bosch, F; Cymbalista, F; Geisler, CH; Ghia, P; Hillmen, P; Moreno, C; Stilgenbauer, S.

In: British Journal of Haematology, Vol. 180, No. 5, 2018, p. 666-679.

Research output: Contribution to journalArticle

Gribben, JG ; Bosch, F ; Cymbalista, F ; Geisler, CH ; Ghia, P ; Hillmen, P ; Moreno, C ; Stilgenbauer, S. / Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. In: British Journal of Haematology. 2018 ; Vol. 180, No. 5. pp. 666-679.
@article{b116fe85b6034128a4ce0a97cb0d02f3,
title = "Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice",
abstract = "{\circledC} 2018 John Wiley & Sons Ltd Ibrutinib is indicated in Europe for the treatment of several B-cell malignancies, including chronic lymphocytic leukaemia (CLL). However, despite the high efficacy and favourable toxicity profile of ibrutinib, recent data suggest that it is not always administered optimally in clinical practice, with an increased tendency for dose reduction and a higher frequency of discontinuation. An expert panel of European haematologists was convened to identify practical issues pertinent to physicians involved in the therapeutic management of ibrutinib-treated CLL patients and here we outline the findings. Practical management recommendations are given for treating patients with ibrutinib and clinical considerations for the management of adverse events (AEs) that can be associated with ibrutinib treatment are addressed. This article highlights that patients should be monitored for treatment emergent adverse events, most of which are mild, transient and generally occur early in therapy and that, even with more challenging AEs, patients can often be maintained on therapy with minimal disruption through careful management. The necessity to use the correct ibrutinib dose, along with increased awareness, vigilance, mitigation and management of AEs, are all recommended to maximise outcomes for CLL patients treated with ibrutinib. {\circledC} 2018 John Wiley & Sons Ltd",
author = "JG Gribben and F Bosch and F Cymbalista and CH Geisler and P Ghia and P Hillmen and C Moreno and S Stilgenbauer",
year = "2018",
doi = "10.1111/bjh.15080",
language = "English",
volume = "180",
pages = "666--679",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",

}

TY - JOUR

T1 - Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice

AU - Gribben, JG

AU - Bosch, F

AU - Cymbalista, F

AU - Geisler, CH

AU - Ghia, P

AU - Hillmen, P

AU - Moreno, C

AU - Stilgenbauer, S

PY - 2018

Y1 - 2018

N2 - © 2018 John Wiley & Sons Ltd Ibrutinib is indicated in Europe for the treatment of several B-cell malignancies, including chronic lymphocytic leukaemia (CLL). However, despite the high efficacy and favourable toxicity profile of ibrutinib, recent data suggest that it is not always administered optimally in clinical practice, with an increased tendency for dose reduction and a higher frequency of discontinuation. An expert panel of European haematologists was convened to identify practical issues pertinent to physicians involved in the therapeutic management of ibrutinib-treated CLL patients and here we outline the findings. Practical management recommendations are given for treating patients with ibrutinib and clinical considerations for the management of adverse events (AEs) that can be associated with ibrutinib treatment are addressed. This article highlights that patients should be monitored for treatment emergent adverse events, most of which are mild, transient and generally occur early in therapy and that, even with more challenging AEs, patients can often be maintained on therapy with minimal disruption through careful management. The necessity to use the correct ibrutinib dose, along with increased awareness, vigilance, mitigation and management of AEs, are all recommended to maximise outcomes for CLL patients treated with ibrutinib. © 2018 John Wiley & Sons Ltd

AB - © 2018 John Wiley & Sons Ltd Ibrutinib is indicated in Europe for the treatment of several B-cell malignancies, including chronic lymphocytic leukaemia (CLL). However, despite the high efficacy and favourable toxicity profile of ibrutinib, recent data suggest that it is not always administered optimally in clinical practice, with an increased tendency for dose reduction and a higher frequency of discontinuation. An expert panel of European haematologists was convened to identify practical issues pertinent to physicians involved in the therapeutic management of ibrutinib-treated CLL patients and here we outline the findings. Practical management recommendations are given for treating patients with ibrutinib and clinical considerations for the management of adverse events (AEs) that can be associated with ibrutinib treatment are addressed. This article highlights that patients should be monitored for treatment emergent adverse events, most of which are mild, transient and generally occur early in therapy and that, even with more challenging AEs, patients can often be maintained on therapy with minimal disruption through careful management. The necessity to use the correct ibrutinib dose, along with increased awareness, vigilance, mitigation and management of AEs, are all recommended to maximise outcomes for CLL patients treated with ibrutinib. © 2018 John Wiley & Sons Ltd

U2 - 10.1111/bjh.15080

DO - 10.1111/bjh.15080

M3 - Article

VL - 180

SP - 666

EP - 679

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -